Anzeige
Erschienen in:
01.11.2009 | Original article
Outcome of MR-guided percutaneous cryoablation for hepatocellular carcinoma
Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences | Ausgabe 6/2009
Einloggen, um Zugang zu erhaltenAbstract
Purpose
To assess the mid-term results of MR-guided percutaneous cryoablation for small hepatocellular carcinoma (HCC).
Methods
Using an argon-based cryoablation system, MR-guided percutaneous cryoablation was performed. The number of tumors was three or fewer. The maximum diameter of tumors was less than 5 cm when solitary and no more than 3 cm when multiple. The Kaplan–Meier method was used to calculate the survival of patients.
Results
Among 15 patients, 16 tumors were treated. The maximum tumor diameter ranged from 1.2 to 4.5 cm, with a mean of 2.5 ± 0.8 cm (mean ± standard deviation). The volume of iceballs measured on MR-images was greater than that of the tumors in all cases. The follow-up period ranged from 10 to 52 months, with a mean of 36.6 ± 12.1 months. One-year and 3-year overall survival were 93.8 and 79.3%, respectively. The complete ablation rate was 80.8% at 3 years. Immediate complications were pneumothorax, hemothorax, and pleural effusion. An ablation zone was not absorbed and content exuded from a scar of the probe tract 4 months after cryoablation in one patient.
Conclusion
MR-guided percutaneous cryoablation appears to be a feasible modality and potentially good option for the treatment of small HCC.